Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

100 Patients Enrolled, Exceeding Target Enrollment of 90 Patients


Topline Results for CAHmelia-204 Anticipated in the Third Quarter of 2024

...

Related Keywords

Javier Szwarcberg ,Spruce Biosciences Inc ,Linkedin ,Drug Administration ,Exchange Commission ,Youtube ,Nasdaq ,Facebook ,Spruce Biosciences ,Chief Executive Officer ,Congenital Adrenal Hyperplasia ,Private Securities Litigation Reform Act ,Markets ,